Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11924463 | 1.00 | DOT1L (0.30) | DOT1L | |
| SCHEMBL14140990 | 0.90 | — | — | |
| SCHEMBL13532237 | 0.89 | — | — | |
| SCHEMBL14038378 | 0.87 | POLRMT (0.31) | DOT1L | |
| SCHEMBL12306914 | 0.87 | — | — | |
| SCHEMBL15682803 | 0.85 | POLRMT (0.39) | — | |
| SCHEMBL9912351 | 0.85 | — | — | |
| SCHEMBL10100148 | 0.84 | — | — | |
| SCHEMBL13532213 | 0.83 | PIK3CD (0.34) | — | |
| SCHEMBL10100144 | 0.82 | CSNK2A2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | DOT1L 3413/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | DOT1L 2852/4885 |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | DOT1L 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.